Trial Profile

A Phase I Trial of Ulixertinib (BVD-523) and Hydroxychloroquine in Patients with Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hydroxychloroquine (Primary) ; Ulixertinib (Primary)
Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer
Focus Adverse reactions
Acronyms UTAH

Most Recent Events

18 Mar 2024 Status changed from active, no longer recruiting to completed.
08 Mar 2023 Planned number of patients changed from 12 to 18.
08 Mar 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com